- Home
- KNSA vs ADPT Comparison
KNSA vs ADPT Comparison
Compare KNSA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- ADPT
- Stock Information
- Founded
- KNSA 2015
- ADPT 2009
- Country
- KNSA United Kingdom
- ADPT United States
- Employees
- KNSA N/A
- ADPT N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNSA Health Care
- ADPT Health Care
- Exchange
- KNSA Nasdaq
- ADPT Nasdaq
- Market Cap
- KNSA 2.6B
- ADPT 2.6B
- IPO Year
- KNSA 2018
- ADPT 2019
- Fundamental
- Price
- KNSA $38.01
- ADPT $16.76
- Analyst Decision
- KNSA Strong Buy
- ADPT Strong Buy
- Analyst Count
- KNSA 7
- ADPT 10
- Target Price
- KNSA $46.86
- ADPT $15.10
- AVG Volume (30 Days)
- KNSA 454.2K
- ADPT 1.7M
- Earning Date
- KNSA 10-28-2025
- ADPT 11-05-2025
- Dividend Yield
- KNSA N/A
- ADPT N/A
- EPS Growth
- KNSA N/A
- ADPT N/A
- EPS
- KNSA 0.47
- ADPT N/A
- Revenue
- KNSA $597,973,000.00
- ADPT $205,216,000.00
- Revenue This Year
- KNSA $53.93
- ADPT $34.41
- Revenue Next Year
- KNSA $25.06
- ADPT $14.03
- P/E Ratio
- KNSA $84.46
- ADPT N/A
- Revenue Growth
- KNSA 55.68
- ADPT 21.60
- 52 Week Low
- KNSA $17.82
- ADPT $4.27
- 52 Week High
- KNSA $42.05
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- KNSA 50.20
- ADPT 58.88
- Support Level
- KNSA $35.53
- ADPT $16.21
- Resistance Level
- KNSA $41.28
- ADPT $17.59
- Average True Range (ATR)
- KNSA 1.50
- ADPT 0.73
- MACD
- KNSA -0.14
- ADPT -0.05
- Stochastic Oscillator
- KNSA 43.13
- ADPT 58.39
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).